A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation
- PMID: 22207766
- DOI: 10.1177/0091270011423661
A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation
Abstract
Mycophenolic acid (MPA) and tacrolimus (TAC) are immunosuppressive agents used in combination with corticosteroids for the prevention of acute rejection after solid organ transplantation. Their pharmacokinetics (PK) show considerable unexplained intraindividual and interindividual variability, particularly in the early period after transplantation. The main objective of the present work was to design a study based on D-optimality to describe the PK of the 2 drugs with good precision and accuracy and to explain their variability by means of patients' demographics, biochemical test results, and physiological characteristics. Pharmacokinetic profiles of MPA and TAC were obtained from 65 stable adult renal allograft recipients on a single occasion (ie, day 15 after transplantation). A sampling schedule was estimated based on the D-optimality criterion with the POPED software, using parameter values from previously published studies on MPA and TAC modeling early after transplantation. Subsequently, a population PK model describing MPA and TAC concentrations was developed using nonlinear mixed-effects modeling. Optimal blood-sampling times for determination of MPA and TAC concentrations were estimated to be at 0 (predose) and at 0.24, 0.64, 0.98, 1.37, 2.38, and 11 hours after oral intake of mycophenolate and TAC. The PK of MPA and TAC were best described by a 2-compartment model with first-order elimination. For MPA, the absorption was best described by a transit compartment model, whereas first-order absorption with a lag time best described TAC transfer from the gastrointestinal tract. Parameters were estimated with good precision and accuracy. While hematocrit levels and CYP3A5 genetic polymorphism significantly influenced TAC clearance, the pharmaceutical formulation and MRP2 genetic polymorphism were retained as significant covariates on MPA absorption and elimination, respectively. The prospective use of the simultaneous D-optimal design approach for MPA and TAC has allowed good estimation of MPA and TAC PK parameters in the early period after transplantation characterized by a very high unexplained variability. The influence of some relevant covariates could be shown.
Similar articles
-
Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.Ther Drug Monit. 2009 Dec;31(6):734-42. doi: 10.1097/FTD.0b013e3181bf8623. Ther Drug Monit. 2009. PMID: 19855314
-
Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.Ther Drug Monit. 2010 Oct;32(5):606-14. doi: 10.1097/FTD.0b013e3181efd715. Ther Drug Monit. 2010. PMID: 20720518
-
Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.Ther Drug Monit. 2017 Feb;39(1):21-28. doi: 10.1097/FTD.0000000000000361. Ther Drug Monit. 2017. PMID: 28030534 Clinical Trial.
-
Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?J Clin Pharmacol. 2019 Mar;59(3):309-325. doi: 10.1002/jcph.1325. Epub 2018 Oct 29. J Clin Pharmacol. 2019. PMID: 30371942 Free PMC article. Review.
-
Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.Br J Clin Pharmacol. 2019 Apr;85(4):746-761. doi: 10.1111/bcp.13850. Epub 2019 Feb 5. Br J Clin Pharmacol. 2019. PMID: 30597603 Free PMC article.
Cited by
-
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.Clin Pharmacokinet. 2013 Sep;52(9):751-62. doi: 10.1007/s40262-013-0069-2. Clin Pharmacokinet. 2013. PMID: 23633119 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.Clin Pharmacokinet. 2013 May;52(5):303-31. doi: 10.1007/s40262-013-0039-8. Clin Pharmacokinet. 2013. PMID: 23475567 Review.
-
Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.Clin Pharmacokinet. 2019 Nov;58(11):1483-1495. doi: 10.1007/s40262-019-00771-3. Clin Pharmacokinet. 2019. PMID: 31055791
-
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Br J Clin Pharmacol. 2016 May;81(5):891-907. doi: 10.1111/bcp.12830. Epub 2016 Feb 26. Br J Clin Pharmacol. 2016. PMID: 26574188 Free PMC article.
-
Population pharmacokinetics study of tacrolimus in liver transplant recipients: a comparison between patients with or without liver cancer before surgery.Front Pharmacol. 2024 Aug 23;15:1449535. doi: 10.3389/fphar.2024.1449535. eCollection 2024. Front Pharmacol. 2024. PMID: 39257396 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical